Methoxyflurane is a general inhalation anesthetic used for induction and maintenance of general anesthesia. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
Methoxyflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Methoxyflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Methoxyflurane also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor and the glycine receptor.
LD50=3600 mg/kg (Orally in rats). Symptoms of overexposure include eye irritation, CNS depression, analgesia, anesthesia, seizures, respiratory depression, and liver and kidney damage.
(R)-warfarin The metabolism of (R)-warfarin can be decreased when combined with Methoxyflurane.
(S)-Warfarin The metabolism of (S)-Warfarin can be decreased when combined with Methoxyflurane.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid The risk or severity of hypertension can be increased when Methoxyflurane is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
1-benzylimidazole The risk or severity of hypertension can be increased when Methoxyflurane is combined with 1-benzylimidazole.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when Methoxyflurane is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when Methoxyflurane is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,5-diiodothyropropionic acid The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Methoxyflurane.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when Methoxyflurane is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarin The metabolism of 4-hydroxycoumarin can be decreased when combined with Methoxyflurane.
4-Methoxyamphetamine The risk or severity of adverse effects can be increased when Methoxyflurane is combined with 4-Methoxyamphetamine.